Logo image of TYRA

TYRA BIOSCIENCES INC (TYRA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:TYRA - US90240B1061 - Common Stock

21.97 USD
+0.85 (+4.02%)
Last: 11/24/2025, 2:08:45 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to TYRA. TYRA was compared to 533 industry peers in the Biotechnology industry. While TYRA has a great health rating, there are worries on its profitability. TYRA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TYRA had negative earnings in the past year.
In the past year TYRA has reported a negative cash flow from operations.
In the past 5 years TYRA always reported negative net income.
In the past 5 years TYRA always reported negative operating cash flow.
TYRA Yearly Net Income VS EBIT VS OCF VS FCFTYRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

With a decent Return On Assets value of -32.92%, TYRA is doing good in the industry, outperforming 64.92% of the companies in the same industry.
TYRA's Return On Equity of -35.03% is fine compared to the rest of the industry. TYRA outperforms 73.92% of its industry peers.
Industry RankSector Rank
ROA -32.92%
ROE -35.03%
ROIC N/A
ROA(3y)-25.06%
ROA(5y)-28.43%
ROE(3y)-26.84%
ROE(5y)-31.19%
ROIC(3y)N/A
ROIC(5y)N/A
TYRA Yearly ROA, ROE, ROICTYRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

TYRA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TYRA Yearly Profit, Operating, Gross MarginsTYRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

TYRA has more shares outstanding than it did 1 year ago.
TYRA has more shares outstanding than it did 5 years ago.
TYRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TYRA Yearly Shares OutstandingTYRA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
TYRA Yearly Total Debt VS Total AssetsTYRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

TYRA has an Altman-Z score of 33.39. This indicates that TYRA is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 33.39, TYRA belongs to the top of the industry, outperforming 95.50% of the companies in the same industry.
TYRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 33.39
ROIC/WACCN/A
WACCN/A
TYRA Yearly LT Debt VS Equity VS FCFTYRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 21.94 indicates that TYRA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 21.94, TYRA belongs to the top of the industry, outperforming 96.25% of the companies in the same industry.
A Quick Ratio of 21.94 indicates that TYRA has no problem at all paying its short term obligations.
The Quick ratio of TYRA (21.94) is better than 96.25% of its industry peers.
Industry RankSector Rank
Current Ratio 21.94
Quick Ratio 21.94
TYRA Yearly Current Assets VS Current LiabilitesTYRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

TYRA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.15%.
EPS 1Y (TTM)-16.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

TYRA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.31% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-34.34%
EPS Next 2Y-21.25%
EPS Next 3Y-15.14%
EPS Next 5Y20.31%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TYRA Yearly Revenue VS EstimatesTYRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
TYRA Yearly EPS VS EstimatesTYRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TYRA. In the last year negative earnings were reported.
Also next year TYRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TYRA Price Earnings VS Forward Price EarningsTYRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TYRA Per share dataTYRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

TYRA's earnings are expected to decrease with -15.14% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-21.25%
EPS Next 3Y-15.14%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TYRA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TYRA BIOSCIENCES INC

NASDAQ:TYRA (11/24/2025, 2:08:45 PM)

21.97

+0.85 (+4.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)03-25 2026-03-25/amc
Inst Owners104.99%
Inst Owner Change-11.2%
Ins Owners3.48%
Ins Owner Change-3.34%
Market Cap1.17B
Revenue(TTM)N/A
Net Income(TTM)-105.83M
Analysts88
Price Target32.13 (46.24%)
Short Float %9.3%
Short Ratio21.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.37%
Min EPS beat(2)5.89%
Max EPS beat(2)12.85%
EPS beat(4)3
Avg EPS beat(4)7.55%
Min EPS beat(4)-0.82%
Max EPS beat(4)12.85%
EPS beat(8)5
Avg EPS beat(8)4.21%
EPS beat(12)9
Avg EPS beat(12)9.47%
EPS beat(16)9
Avg EPS beat(16)-8.11%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)4.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.45%
EPS NY rev (1m)0%
EPS NY rev (3m)0.93%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.88
P/tB 3.88
EV/EBITDA N/A
EPS(TTM)-1.87
EYN/A
EPS(NY)-2.22
Fwd EYN/A
FCF(TTM)-1.63
FCFYN/A
OCF(TTM)-1.63
OCFYN/A
SpS0
BVpS5.67
TBVpS5.67
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -32.92%
ROE -35.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.06%
ROA(5y)-28.43%
ROE(3y)-26.84%
ROE(5y)-31.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.59%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 21.94
Quick Ratio 21.94
Altman-Z 33.39
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)177.58%
Cap/Depr(5y)324.83%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.95%
EPS Next Y-34.34%
EPS Next 2Y-21.25%
EPS Next 3Y-15.14%
EPS Next 5Y20.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-27.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-25.55%
EBIT Next 3Y-21.25%
EBIT Next 5YN/A
FCF growth 1Y-97.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-98.41%
OCF growth 3YN/A
OCF growth 5YN/A

TYRA BIOSCIENCES INC / TYRA FAQ

What is the fundamental rating for TYRA stock?

ChartMill assigns a fundamental rating of 3 / 10 to TYRA.


What is the valuation status of TYRA BIOSCIENCES INC (TYRA) stock?

ChartMill assigns a valuation rating of 0 / 10 to TYRA BIOSCIENCES INC (TYRA). This can be considered as Overvalued.


How profitable is TYRA BIOSCIENCES INC (TYRA) stock?

TYRA BIOSCIENCES INC (TYRA) has a profitability rating of 1 / 10.


What is the financial health of TYRA BIOSCIENCES INC (TYRA) stock?

The financial health rating of TYRA BIOSCIENCES INC (TYRA) is 8 / 10.


What is the earnings growth outlook for TYRA BIOSCIENCES INC?

The Earnings per Share (EPS) of TYRA BIOSCIENCES INC (TYRA) is expected to decline by -34.34% in the next year.